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The tumor necrosis factor superfamily (TNFSF) members play pivotal roles in embryonic
development of lymphoid tissue and their homeostasis. RANKL (Receptor activator of NF-
κB ligand, also called TRANCE, TNFSF11) is recognized as an important player in bone
homeostasis and lymphoid tissue formation. In its absence bone mass control is deregu-
lated and lymph nodes fail to develop. While its function in bone is well described, there is
still little functional insight into the action of RANKL in lymphoid tissue development and
homeostasis. Here we provide an overview of the known functions of RANKL, its signal-
ing receptor RANK and its decoy receptor OPG from the perspective of lymphoid tissue
development and immune activation in the mouse. Expressed by the hematopoietic lym-
phoid tissue inducing (LTi) cells and the mesenchymal lymphoid tissue organizer (LTo) cells,
RANKL was shown to stimulate Lymphotoxin (LT) expression and to be implicated in LTi
cell accumulation. Our recent finding that RANKL also triggers proliferation of adult lymph
node stroma suggests that RANKL may furthermore directly activate LTo cells. Beyond
bone, the RANKL-RANK-OPG triad plays important roles in immunobiology that are waiting
to be unraveled.
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INTRODUCTION
Tumor necrosis factor (TNF) and Lymphotoxin (LT) were iden-
tified as the first members of a large family, now called the TNF-
superfamily (SF). Not surprisingly, the receptors for these proteins
also constitute a SF with sequence homology, named TNF Recep-
tor (TNFR) SF. A hallmark of these ligand-receptor pairs lies in a
threefold symmetry, where by the oligomeric binding arrangement
amplifies their avidity and introduces flexibility. Further complex-
ity arises through different partner affinities and generation of
soluble ligand and receptor forms (Bodmer et al., 2002). RANKL
(TNFSF11) is the ligand of two receptors, RANK (TNFRSF11a)
and OPG (TNFRSF11b). OPG (osteoprotegerin) was the first of
this protein triad to be discovered (Simonet et al., 1997) in a search
for an inhibitor of osteoclastogenesis (Tsuda et al., 1997). OPG-
ligand was then isolated and cloned using OPG as bait (Lacey et al.,
1998; Yasuda et al., 1998). OPG-ligand turned out to be identical
to TRANCE (TNF-related activation induced cytokine), cloned
during a search for apoptosis-regulatory genes in T cells (Wong
et al., 1997b), and RANKL (Receptor activator of NF-κB) iden-
tified as the ligand for RANK that had attracted attention for its
homology to CD40 (Anderson et al., 1997). The affinity of RANKL
for OPG is 1000-fold higher than for RANK (Nakagawa et al.,
1998), which is dependent on the ability of OPG to homodimerize
(Schneeweis et al., 2005). OPG is also a ligand for TNF-related
apoptosis-inducing ligand (TRAIL; Emery et al., 1998), however,
its affinity for TRAIL is 10,000 times less compared to RANKL
(Body et al., 2006) questioning the in vivo relevance of OPG-
TRAIL interaction. There is now an emerging consensus to refer
to the receptor as RANK and, as a consequence and for simplicity,
its ligand is called RANKL. The acronym OPG has remained in use.
The discovery of RANK, RANKL, and OPG in bone and the
immune system raises the question of its evolutionary origins. The
genes arose simultaneously during ontogeny of bony fish as evi-
denced by gene sequence identification and presence of resorption
and remodeling activity of vertebrate mineralized tissue (Witten
and Huysseune, 2009). They therefore postdate the formation of
the primordial immune system comprising a primitive thymus and
lymphoid structures associated with exposed sites. However, they
preceded the development of lymph nodes (LNs) and germinal
centers arising in amphibians and the emergence of LT β receptor,
a key molecule in lymphoid development (Glenney and Wiens,
2007; see below). It is therefore likely that the RANK-RANKL-
OPG protein triad was co-opted by the advanced immune system
for higher order structure together with an efficient regulation of
immune cell output from the bone marrow before genesis of LT β
receptor-regulated lymphoid tissues.
RANKL is a type-II transmembrane protein but can also exist
in a soluble form by ectodomain shedding and alternative splicing
(Ikeda et al., 2001; Hikita et al., 2006; Baud’huin et al., 2007). OPG
comprises two C-terminal regions homologous to death domains
of TNFR1 or TRAIL receptor, which were found to be func-
tional when OPG was expressed with a transmembrane sequence
(Yamaguchi et al., 1998). Natural OPG is unlikely to transmit
signals because it misses the transmembrane sequence and is
secreted (Simonet et al., 1997). RANK comprises a transmem-
brane region and a large cytoplasmic domain. Upon interaction
with the RANKL trimer RANK undergoes homotrimerization and
activates recruitment of TNFR-associated factors (TRAFs; Galib-
ert et al., 1998; Wada et al., 2006). RANK binds five of the six
known TRAF-proteins but TRAF6 seems particularly important
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for RANK signaling, because TRAF6−/−mice present similar phe-
notypes as Rank−/−mice (Naito et al., 1999). RANK signaling cas-
cades were mostly deciphered in the myeloid lineage and include
the canonical and the non-canonical NF-κB pathways (Raju et al.,
2011). In mammary glands RANK-activation intersects with pro-
liferative cues through cyclin D1, Id2, and Id4 (Schramek et al.,
2011). RANK was recently found to play a role in mammary and
in hair follicle epithelial stem cell activation (Schramek et al., 2010;
Duheron et al., 2011) and to induce intestinal microfold cells (M
cells) differentiation via the Ets transcription factor Spi-B (Kanaya
et al., 2012).
RANKL IN BONE AND HEMATOPOIESIS
A number of reviews have been published on the role of these pro-
teins in regulating bone mass (Suda et al., 1999; Walsh and Choi,
2003; Baud’huin et al., 2007; Leibbrandt and Penninger, 2010).
Rankl−/− and Rank−/− mice present osteopetrosis and lack of
teeth (Dougall et al., 1999; Kong et al., 1999), whereas Opg−/−
animals exhibit osteoporosis (Bucay et al., 1998; Mizuno et al.,
1998; Yun et al., 2001). RANK activates the differentiation of bone
matrix degrading osteoclasts (OCL) from myeloid precursor cells
(Yasuda et al., 1998; Hsu et al., 1999; Figure 1). RANKL and OPG
are synthesized by the bone mesenchymal lineage and are under
inflammatory and hormonal control (Udagawa et al., 1999; Takeda
et al., 2003; Nakashima et al., 2011; Xiong et al., 2011). Another
source of RANKL is activated T cells that can cause abnormal
bone resorption by triggering osteoclastogenesis (Takayanagi et al.,
2000; Sato et al., 2006).
T cell lymphopoiesis itself underlies RANK regulation
as Rank−/− mice present a block in the progression to
CD4−CD8−CD44−CD25− thymocytes (Kong et al., 1999).
Recently it was shown that also Vγ5+ T cells are under RANK
FIGURE 1 | RANKL function in the bone, the adaptive immune system
and the vascular system. (A) RANKL produced by bone marrow stroma
(osteoblasts and osteocytes) directs the differentiation of preosteoclasts of
the myeloid lineage into mature osteoclasts. Stroma-derived OPG
negatively regulates RANKL-RANK interaction. (B) Activated T cells express
RANKL that stimulates dendritic cell survival and maturation. (C)
Endothelium is a source for RANKL and OPG. RANK-activation of
endothelial cells supports cell survival and promotes angiogenesis.
regulatory action (Roberts et al., 2012). In fact RANK signaling is
a key event in the early stages of medullary thymic epithelial cell
(mTEC) formation, and its cooperation with LT and CD40 signals
is required to establish a fully developed medullary microenvi-
ronment (Rossi et al., 2007; Akiyama et al., 2008; Hikosaka et al.,
2008; Mouri et al., 2011). mTEC play a crucial role in self-tolerance
by eliminating self-reactive αβT cells and by regulating the early
production of γδT cells. Thymic CD3−CD4+ lymphoid tissue
inducing (LTi) cells and Vγ5+ thymocytes as well as later aris-
ing CD4+CD8− single positive thymocytes and γδT cells are
equipped with RANKL (Rossi et al., 2007; Hikosaka et al., 2008;
Roberts et al., 2012). RANK and OPG are expressed by mTECs
(Hikosaka et al., 2008). Animals defective in RANK signaling
also display abnormal B cell hematopoiesis and hypogammaglob-
ulinemia (Dougall et al., 1999; Kong et al., 1999). Although B
cells express RANK, in particular in response to activation (Yun
et al., 1998; Perlot and Penninger, 2012), a B cell-specific RANK
knock-out mouse does not reproduce this phenotype (Perlot and
Penninger, 2012), suggesting that the defect lies in bone marrow
or splenic stroma.
RANKL IN EARLY STAGES OF SECONDARY LYMPHOID
ORGAN DEVELOPMENT
RANK and RANKL-deficient animals display a complete absence
of LNs, defects in Peyer’s patches (PPs) and cryptopatches (CPs)
and abnormalities of the spleen (Dougall et al., 1999; Kong et al.,
1999; Kim et al., 2000; Knoop et al., 2011; Perlot and Penninger,
2012). Therefore the RANK-RANKL-OPG axis shares with the
LT and TNFα pathways the control of molecular and cellular
processes determinant in secondary lymphoid organ (SLO) devel-
opment (Tumanov et al., 2003; Fritz and Gommerman, 2010).
SLO formation is initiated around embryonic day (E) 15 with
the recruitment of the hematopoietic LTi cells to a rudimentary
organ anlage composed of mesenchymal and endothelial stroma
(White et al., 2007; Vondenhoff et al., 2009; Benezech et al., 2011).
The recruitment process is dependent on the chemokine CXCL13
produced by precursors of lymphoid tissue organizer (LTo) cells
stimulated by neuronal production of retinoic acid (van de Pavert
et al., 2009). This step is followed by a cross-talk between LTi
cells that express RANK, RANKL, and LT, and LTo precursors
that carry the LT receptor LTβR. LTβR engagement induces LTo
cells to express RANKL and chemokines to attract larger numbers
of LTi cells that upon clustering with LTo cells initiate LN orga-
nization (Cupedo and Mebius, 2005; Koning and Mebius, 2011;
Figure 2).
In view of the finding that LTi cell recruitment is LT indepen-
dent (Eberl et al., 2004; White et al., 2007; Vondenhoff et al., 2009)
the question arises whether LTi cell accumulation is regulated by
RANK. Both Rankl−/− and Ltα−/− mice have lower number of
LTi cells in mesenteric LNs of newborn mice (Kim et al., 2000).
TRAF6−/−mice display fewer LTi cells in mesenteric LNs at E 17.5
but not at E15.5 (Yoshida et al., 2002). Administration of RANK-
Fc antagonist led to a partial reduction in LTi cells, with a more
prominent effect in mesenteric LNs (Eberl et al., 2004). Therefore,
although current data do not unambiguously support RANKL as
a direct regulator of LTi cell numbers, they sustain the concept
that RANKL is instrumental for LTi cell accumulation. Of note,
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FIGURE 2 | RANKL-dependent amplification loops in SLO development.
SLO development during embryogenesis is initiated by the recruitment of
lymphoid tissue inducer (LTi) cells to a rudimentary organ anlage composed
of mesenchymal lymphoid tissue organizer (LTo) cell progenitors. This step
is followed by a cross-talk between LTi cells that express RANKL, RANK,
and LTαβ and LTo cells that carry LTβR . Engagement of the latter induces
the maturation of LTo cells to express RANKL and chemokines that
attract larger numbers of LTi cells that upon clustering with LTo cells initiate
LN organization. LTo cells also express RANKL. The current model of LN
development indicates that a positive feedback loop takes place between
LTo and LTi cells via RANKL-RANK and LTαβ-LTβR amplifying the early
stages of LN development . If LTo cells expressed also RANK, a second
(autocrine) loop may occur, leading to a direct activation of LTo cells .
RANK signaling mediators include Id2 (Kim et al., 2011), a fac-
tor indispensable for LTi cell formation (Yokota et al., 1999). It is
hence plausible that Id2 is implicated in RANK regulation of LTi
cell numbers and function.
In the current model of LN development a positive feedback
loop takes place between LTi and LTo cells (Figure 2). RANK
signaling in LTi cells increases the expression of LT that upon
binding to LTβR of LTo cells induces RANKL production, thus
amplifying the early stages of LN development (Yoshida et al.,
2002; Koning and Mebius, 2011; Roozendaal and Mebius, 2011).
In support for such a feedback loop is the observation that RANKL
expression is up to 10-fold higher in LTo cells than in LTi cells
(Sugiyama et al., 2012). However, it is unlikely that the function
of RANKL in SLO development is limited to the induction of LT
by LTi cells and the creation of the amplification loop. Firstly, LT
is upregulated by a number of other factors, such as IL-7, TNFα,
and CXCL13 (Ansel et al., 2002). Indeed PPs are LT-dependent
but develop in Rankl−/− mice. Second, mucosal LNs develop in
LTβ−/− mice but not in Rankl−/− mice (Alimzhanov et al., 1997;
Koni et al., 1997). Finally, administration of an LTβR-agonistic
antibody to Rankl−/− embryos cannot rescue LN genesis (Kim
et al., 2000).
LTβR signaling in mTECs induces RANK expression (Mouri
et al., 2011). We have recently shown that RANK is expressed
in adult LN stroma and induces hyperproliferation of reticular
fibroblastic and vascular cells (Hess et al., 2012). Expression of
both RANK and RANKL by LTo cells may therefore trigger a
second (autocrine) loop leading to a direct activation of these
cells (Figure 2). In addition, vascular endothelial cells express
RANK, RANKL, and OPG that together regulate angiogenesis
(Kim et al., 2003; Benslimane-Ahmim et al., 2011; Sugiyama et al.,
2012; Figure 1).
RANKL AND SLO GROWTH
A number of observations support a role of RANKL in SLO
growth. The LNs that developed after neutralization of RANK
signaling in embryos were smaller (Eberl et al., 2004; Sugiyama
et al., 2012). PPs, CPs, and isolated lymphoid follicles (ILFs) were
reduced in size in Rankl−/− mice (Knoop et al., 2011), and post-
natal RANKL overproduction led to massive LN hyperplasia (Hess
et al., 2012). Recruitment of immune cells and stromal cell divi-
sion stand out among possible regulatory mechanisms of SLO size.
Lymphocyte recruitment into SLO anlage coincides with matura-
tion of LTo cells to produce high levels of chemokines and cell
adhesion molecules (Honda et al., 2001; Finke et al., 2002; Luther
et al., 2003; Cupedo et al., 2004b; White et al., 2007; Benezech et al.,
2011). In mice with postnatal LN hyperplasia RANKL upregulates
CXCL13, CCL19, MAdCAM-1, and VCAM-1 gene transcription
in adult fibroblastic reticular cells (FRCs) and vascular cells (Hess
et al., 2012). Therefore, RANKL could directly boost immune cell
accumulation by increased chemokine and adhesion factor output.
While recruitment of stromal precursors from surrounding tissue
or bone cannot be excluded, CD45-negative cells label for the cell
division marker Ki-67 as early as E16 (Eberl et al., 2004; White
et al., 2007). Although this proliferation appears to be dependent
on LT (White et al., 2007), it is unclear whether the proliferat-
ing cells are endothelial cells, precursor or mature LTo cells. We
have found that RANKL stimulates FRC and endothelial cell pro-
liferation (Hess et al., 2012). Further support for a functionally
important role of RANKL in cell proliferation stems from findings
that thymic mTECs and skin keratinocyte cell growth is accelerated
in response to RANK stimulation (Hikosaka et al., 2008; Duheron
et al., 2011).
TOWARD A ROLE OF RANKL IN B CELL RECRUITMENT AND
FOLLICLE ORGANIZATION
B cell recruitment and organization into follicles occur in a
CXCL13-dependent manner at later stages of SLO formation
(Ansel et al., 2000; Cupedo et al., 2004a). B cell follicular den-
dritic cells (FDCs) and the recently identified marginal reticular
cells (MRCs), both mesenchymal cell types, are the main produc-
ers of this chemokine (Ansel et al., 2000; Katakai et al., 2008). First
supportive evidence for a role of RANKL in B cell recruitment and
organization was provided after the rescue of LNs by exogenous
IL-7 in TRAF6−/− mice: it was noted that in these LNs B cells and
FDCs were absent (Yoshida et al., 2002). However, because TRAF6
is also a signaling component for TNFR, a critical receptor for
FDC formation (Rennert et al., 1998; Endres et al., 1999), a role of
RANK signaling in B cell recruitment cannot be directly invoked.
More direct evidence was provided by administration of a RANKL-
neutralizing antibody to embryos. This resulted in reduced LN B
cells numbers, misplaced FDCs, and reduced VCAM-1 staining
(Sugiyama et al., 2012). In addition, Knoop et al. (2011) noted an
absence of B cells in small intestine CPs of Rankl−/− mice and
observed that most stromal cells in the B cell compartment lacked
VCAM-1 and CXCL13 expression. Finally, postnatal RANKL over-
expression resulted in an increase in small but clearly defined
B cell follicles, which all comprised FDCs (Hess et al., 2012).
Three possible scenarios can be advanced to explain these phe-
nomena: (i) RANKL increases the bone marrow B cell output, (ii)
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CXCL13 production by FDCs and/or MRCs is under RANKL pos-
itive control, (iii) RANK-signaling promotes MRC and/or FDC
differentiation. Although the first scenario appears plausible in
view of the known action of RANKL in the bone, so far, there is
no experimental support for this idea. The rise in LN B cell num-
bers in response to RANKL overproduction is not accompanied
by an expansion in splenic transitional B cell subsets (Hess et al.,
2012). As for the second model, there is evidence that RANKL
upregulates CXCL13 gene transcription in FRCs, however the
level of induction was low (Hess et al., 2012). Lastly, reduction
of VCAM-1 expression by FDCs is indicative of a requirement of
RANK-signaling for terminal differentiation of FDCs. In keep-
ing with this idea, reduced CXCL13 expression by FDCs could be
the consequence of FDC dysfunction. It is intriguing that MRCs,
which have been proposed to function as FDC precursors, express
RANKL (Katakai et al., 2008). Cells that bear resemblance to LN
MRCs have also been found in the spleen, PP, and ILF on the
grounds of RANKL expression and independence of LTβR sig-
naling (Taylor et al., 2007; Katakai et al., 2008). The polarized
expression of RANKL beneath the follicle-associated epithelium
may be necessary to focus its activity of inducing differentiation
of intestinal M cells, cells specialized in the transport of antigen to
the underlying lymphoid tissue (Knoop et al., 2009). It is plausi-
ble that RANKL jointly regulates FDC differentiation and (native)
antigen access.
RANKL AND THE ADAPTIVE IMMUNE RESPONSE
Activated CD4 and CD8 T cells express surface and soluble RANKL
(Josien et al., 1999; Wang et al., 2002; Figure 1). Dendritic cells
are of the same lineage as OCL and express RANK (Anderson
et al., 1997). RANKL confers to DCs better survival with more
notable effects on in vitro generated DCs and in combination
with other TNFSF members (Wong et al., 1997a; Dougall et al.,
1999; Josien et al., 2000; Williamson et al., 2002). Stimulation
of DCs results in production of pro-inflammatory cytokines IL-
6, IL-1β, and T cell differentiation factors IL-12, IL-15 (Josien
et al., 1999). However, other reports have noted anti-inflammatory
activity for RANKL. In a model of oral tolerance, RANKL stim-
ulation of DCs has been associated with tolerance induction
(Williamson et al., 2002). An anti-inflammatory effect was also
noted for RANKL-stimulated Langerhans cells and macrophages
(Maruyama et al., 2006; Yoshiki et al., 2009). This discrepancy
may be due to low RANK expression level in immature DCs;
its expression being upregulated in response to Toll-like recep-
tor (TLR) ligands or inflammatory cytokines (Hochweller and
Anderton, 2005). Another explanation could be a redundancy with
other TNFRSF members such as its close homolog CD40 (Bach-
mann et al., 1999). Alternatively, activated DCs express OPG, thus
inhibiting RANKL (Schoppet et al., 2007). Except for a reduction
in Langerhans cell numbers (Barbaroux et al., 2008), there is little
experimental support that the RANK-RANKL-OPG triad controls
DC development in vivo (Dougall et al., 1999).
Th17 T cells represent an important osteoclastogenic T cell type
by robust RANKL production and activation of RANKL release by
mesenchymal cells (Sato et al., 2006). This T cell type is of par-
ticular importance in progressive periodontitis, a dental disease
characterized by destruction of alveolar bone with high prevalence
of bacteria such as Porphyromonas gingivalis (Kajiya et al., 2010).
In this disease, periodontal ligament fibroblasts are an important
source of RANKL when stimulated by microbial products includ-
ing TLR ligands. TLRs are also expressed by osteoclast precursors
and OCL and their stimulation promotes osteoclastogenesis and
maturation of OCL. Interestingly, gingival Langerin-expressing
DCs have recently been shown to control inflammation in P. gin-
givalis-induced periodontitis and therefore reduce alveolar bone
loss (Arizon et al., 2012). It is yet unclear whether this occurs via a
direct RANKL-induced DC anti-inflammatory activity.
CONCLUSION
The RANK-RANKL-OPG axis plays a recognized role in bone
homeostasis through the regulation of osteoclastogenesis. It is also
implicated in SLO development and regulation of the immune
response. There are many incentives to answer remaining ques-
tions. In addition to a restless curiosity of the researcher, tertiary
lymphoid tissues that arise in inflamed tissue rely on similar if
not identical cellular dialogs as those found in SLO development.
Defining RANKL function in lymphoid tissue development will
open new therapeutic avenues to treat inflammatory diseases and
provide new strategies for vaccine development.
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